NASDAQ:TLPH - Nasdaq - US00444T2096 - Common Stock - Currency: USD
0.51
+0.02 (+4.59%)
The current stock price of TLPH is 0.51 USD. In the past month the price decreased by -7.42%. In the past year, price decreased by -47.5%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 55.95 | 729.65B | ||
JNJ | JOHNSON & JOHNSON | 15.43 | 373.01B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 20.73 | 331.61B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.2 | 233.10B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.56 | 225.96B | ||
MRK | MERCK & CO. INC. | 10.14 | 198.30B | ||
PFE | PFIZER INC | 7.27 | 132.75B | ||
SNY | SANOFI-ADR | 11.34 | 122.83B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.6 | 98.52B | ||
GSK | GSK PLC-SPON ADR | 9.24 | 83.58B | ||
ZTS | ZOETIS INC | 28.27 | 75.76B | ||
HLN | HALEON PLC-ADR | 22.14 | 49.84B |
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. The firm's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The firm is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.
TALPHERA INC
1850 Gateway Drive, Suite 175
San Mateo CALIFORNIA US
Employees: 13
Phone: 16502163500
The current stock price of TLPH is 0.51 USD. The price increased by 4.59% in the last trading session.
The exchange symbol of TALPHERA INC is TLPH and it is listed on the Nasdaq exchange.
TLPH stock is listed on the Nasdaq exchange.
9 analysts have analysed TLPH and the average price target is 4.25 USD. This implies a price increase of 733.34% is expected in the next year compared to the current price of 0.51. Check the TALPHERA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TALPHERA INC (TLPH) has a market capitalization of 10.46M USD. This makes TLPH a Nano Cap stock.
TALPHERA INC (TLPH) currently has 13 employees.
TALPHERA INC (TLPH) has a resistance level at 0.53. Check the full technical report for a detailed analysis of TLPH support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TLPH does not pay a dividend.
TALPHERA INC (TLPH) will report earnings on 2025-08-12.
TALPHERA INC (TLPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.45).
The outstanding short interest for TALPHERA INC (TLPH) is 1.14% of its float. Check the ownership tab for more information on the TLPH short interest.
ChartMill assigns a fundamental rating of 2 / 10 to TLPH. While TLPH seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months TLPH reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 49.44% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -77.65% | ||
ROE | -207.95% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to TLPH. The Buy consensus is the average rating of analysts ratings from 9 analysts.